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VASCULAR BIOLOGY
Flt-1 regulates vascular endothelial cell migration via a protein tyrosine
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Protein tyrosine kinase 7 (PTK7) is a
pseudokinase whose precise function in
regulating angiogenesis remains un-
known. The purpose of this study was to
define the mechanisms by which PTK7
promotes vascular endothelial growth
factor-A (VEGF-A)–induced angiogenesis
in vivo and in vitro. Immunoblotting was
used to measure PTK7 expression in sev-
eral types of vascular endothelial cells.
Using both immunoprecipitation and im-
munoblotting, PTK7 was found to join a
receptor complex with Flt-1 (VEGFR1),
but not with KDR/Flk-1 (VEGFR2) or with
Flt-4 (VEGFR3). By surface plasmon reso-
nance analysis, the interaction between
Flt-1 and PTK7 was confirmed and found
to be intensified by VEGF-A. Flt-1 phos-
phorylation and downstream signals of
Akt, and focal adhesion kinase (FAK) thus
induced were down-regulated by inhibi-
tion of PTK7 expression using siRNA.
Moreover, PTK7 overexpression in endo-
thelial cells resulted in enhanced angio-
genesis in vitro. In contrast, neovascular-
ization induced in vivo by VEGF-A pellets
was significantly decreased by injection
of siRNA targeting PTK7. These data sug-
gest that PTK7 serves an essential role in
Flt-1–mediated angiogenesis. (Blood.
2011;117(21):5762-5771)
Introduction
Protein kinases regulate the functions of many proteins by catalyz-
ing covalent attachment of phosphate to serine, threonine, and
tyrosine residues in their targets. Genome-wide analyses have
revealed that 2%-3% of all eukaryotic genes encode proteins
containing a kinase domain, used to regulate cellular homeosta-
sis.1-3 Unexpectedly, some protein kinases ( 10%) lack one or
more of the conserved amino acids required for kinetic activity, and
are thus predicted to be inactive. These kinases are termed
pseudokinases or defective kinases. However, unlike tyrosine
kinases, such pseudokinases have not been well studied and their
physiologic roles remain obscure.
One such pseudokinase, protein tyrosine kinase 7 (PTK7, also
termed colon carcinoma kinase 4 [CCK4]) was originally identified
as a protein overexpressed in several cancer cells, including
melanoma4 and colon carcinoma.5 Structurally, PTK7 consists
of a single peptide, with 7 immunoglobulin-like extracellular
domains, a transmembrane region, and a C-terminal domain
with homology to tyrosine kinases. Although no specific ligand
for PTK7 has yet been identified, mouse embryos expressing a
truncated form of PTK7 die perinatally, with profound defects in
neural tube closure and orientation of inner ear stereociliary
bundles, indicating that PTK7 is involved in polarity regulation
within cell planes.6 Interestingly, PTK7 is evolutionarily highly
conserved among organisms as diverse as hydra (which occupy
a near-basal position among metazoa) and humans.7 These
studies indicate that, despite absence of both kinetic activity and
known function, PTK7 may play an essential role in survival and
embryogenesis.
Angiogenesis is controlled by various positive and negative
regulators, including growth factors, cytokines, lipid metabolites,
and cryptic hemostatic protein fragments. Of the various angio-
genic pathways, the role of vascular endothelial growth factors
(VEGFs) and their receptors (VEGFRs) in vascularization have
been better characterized than other systems.8,9 VEGF-A binds with
high affinity to Flt-1 (VEGFR1) and Flk-1/KDR (VEGFR2), an
interaction that is essential for angiogenesis. There is now consen-
sus that Flk-1/KDR is the major mediator of the mitogenic,
angiogenic, and permeability-enhancing effects of VEGF-A in
many pathologic states.10 However, the role of Flt-1 in angiogen-
esis remains controversial. Some reports have claimed that Flt-1
positively affects angiogenesis and vascular endothelial cell migra-
tion.11,12 In contrast, soluble Flt-1 is considered to function as a
negative regulator and a decoy factor in angiogenesis. Contrary to
these reports, other studies, using knockdown or knockout mouse
models13-15 have found that Flt-1 increases vascular endothelial cell
growth and proliferation, suggesting that Flt-1 is critical in
facilitating angiogenesis. Shin and colleagues have reported that
PTK7 is present in vascular endothelial cells (VECs) and plays an
important role in human umbilical vein endothelial cell (HUVEC)
migration.16 These authors have found that HUVEC migration was
inhibited in vitro and in vivo when PTK7 expression was reduced.
However, the exact mechanisms by which PTK7 regulates cell
migration and angiogenesis were not explored.
The purpose of the present study was to define the mechanisms
by which PTK7 promotes VEGF-induced angiogenesis, using both
in vivo and in vitro models.
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Methods
Reagents
Mouse monoclonal antibody against human PTK7 (clone 1A8) was
purchased from GeneTex. Human recombinant VEGF-A165, mouse recom-
binant VEGF-A164, and goat polyclonal antibody against PTK7 were
purchased from R&D Systems. Anti–human VEGFR1 (Flt-1), anti–human
VEGFR2 (KDR), anti–phospho-Tyr (P99), and anti–human VEGFR-3
(Flt-4) were from Santa Cruz Biochemicals. Anti–phospho-tyrosine kinase,
anti–phospho-Flt-1 (Tyr 1213), and anti–phospho-KDR (Tyr1054) were
from Millipore. Mouse anti-FAK was purchased from Calbiochem, and
both anti–phospho-FAK (Tyr 567/577) and anti–phospho-Akt (Ser/Thr)
were from Cell Signaling Technology. Anti–mouse Akt was from Cell
Sciences Inc. Murine PlGF was purchased from Sigma-Aldrich.
Cell culture
HUVECs (Clonetics) were cultured in EGM2-MV medium (Lonza).
Bovine arterial endothelial cell (BAE) and the mouse endothelial cell line,
MS1 (a kind gift from Dr Patricia D’Amore, Boston MA), derived from
primary murine cells by immortalization with temperature-sensitive SV40
large T antigen,17 were cultured in Dulbecco modified Eagle medium
(DMEM)/F12, with 10% (vol/vol) fetal bovine serum (Invitrogen), respec-
tively. HUVECs were used between passages 5 and 10. As a negative
control, HEK293 cells and NIH 3T3 fibroblasts (ATCC) were maintained in
DMEM with 10% (vol/vol) FBS. Cells were grown under 5% (vol/vol) CO2
at 37°C and media were changed every 2-3 days.
Immunoprecipitation
Cell lysates for immunoprecipitation were prepared in mammalian cell lysis
buffer supplemented with a protease inhibitor cocktail (Roche). Superna-
tants were collected after centrifugation at 15 000g for 20 minutes at 4°C.
Between 350-500 g of total protein was incubated with 13 g of
appropriate antibody for at least 3 hours and 50 L of protein
A/G-conjugated agarose beads for an additional hour at 4°C. Beads were
washed 3 times with lysis buffer and immunoprecipitates resuspended in
2 SDS sample buffer.
Western blot analysis
Total protein concentrations of supernatant fractions were determined
using the BCA protein assay (BioRad Laboratories). Equal amounts of
protein aliquots were boiled in equal volumes of 2 SDS Laemmli
sample buffer, and resolved on 8% (wt/vol) or 10% (wt/vol) SDS-PAGE.
Proteins were next transferred to polyvinylidene difluoride (PVDF)
membranes and probed overnight with primary antibodies. Immunoreac-
tive bands were detected with horseradish peroxidase–conjugated
secondary antibodies and visualized by the enhanced chemilumines-
cence technique.
Plasmids
cDNAs encoding a fragment of human PTK7 (PTK715-59) and full-length
PTK7 were amplified by PCR from a HeLa cell cDNA library, using Pfu
polymerase (Stratagene). Each PCR fragment was inserted into the
pcDNA3.1 expression vector (Invitrogen) and plasmids were transformed
into Escherichia coli JM109 cells. Transformed JM109 cells were grown in
1 L of Luria broth (LB) and recombinant plasmids were purified using the
QIAfilter approach (QIAGEN). Both PTK7 cDNA clones were fully
sequenced.
Purification of proteins
To construct PTK7-GST and fragment PTK715-59-GST expression vectors,
the cDNAs amplified in the previous section were introduced into the
GST expression vector pGEX-5X (GE Healthcare). These vectors were
introduced into E coli L21/DE3. Transformed cells were grown in LB
medium with ampicillin, and after isopropyl-L-thio--D-galactopyrano-
side (IPTG) induction, were spun down, washed in PBS, and sonicated
in the presence of 35mM octyl-glucopyranoside in PBS (pH 7.2). Cell
debris was removed by centrifugation, and the GST-PTK7 or GST-
fragment-PTK7 proteins purified on a GST affinity column (Amersham
Biosciences). To construct the Flt-1 and Flk-1/KDR-GST plasmid,
cDNA encoding Flt-1 and Flk-1 was amplified and inserted into the
vector described. The plasmid was transformed into CHO cells maintained
in Ham-F12 medium (GIBCO-BRL) supplemented with 10% (vol/vol)
FCS in p60 plates at 5  105 cells per well. Transductions were carried
out 1 day after initial plating using 10 g of the pCl-Neo constructs and
24 L of lipofectamine in a total volume of 1 mL medium/well.
Transfected cells were selected using G418 sulfate (Geneticin;
GIBCO-BRL) at 500 g/mL and cloned by limiting dilution, and
clones producing the highest levels of PTK7 proteins as assessed by
ELISA were expanded for protein production. Flt-1-GST and Flk-1/
KDR-GST were purified from tissue culture supernatants by affinity
chromatography on an anti-Bb column. The eluate was concentrated
and the protein subjected to final purification by gel filtration using
Biacore buffer on Superdex 200. To cleave GST-tag from proteins, the
eluted fractions were dialyzed overnight at 4°C against 5mM CaCl2,
100 mM NaCl, and 50mM Tris (pH 8.0), and incubated 16 hours at
room temperature with 1.2 g of bovine factor Xa (Promega) per
100 g of fusion protein. Digestion products were resolved by on
3%-12% Tris-Bis Native Gel (Invitrogen) or SDS-PAGE. After electro-
phoresis, the gels were stained with Coomassie Blue R-250 and
then destained.
Surface plasmon resonance analysis
Analyses were performed using a BIAcore 3000 instrument (GE Health-
care). Flt-1 or Flk-1/KDR was immobilized onto CM5 sensor chip
(GE Healthcare) surfaces, using an amine coupling kit (GE Healthcare)
according to the manufacturer’s instructions. Protein binding was measured
at a flow rate of 10 L/min in 145mM NaCl/10mM HEPES (pH 7.4)
containing varied concentrations of analyte proteins, unless otherwise
indicated. As a control, each analyte protein was injected over a surface
with no immobilized protein, to yield a blank sensorgram for subtraction of
bulk refractive index background. Surface regeneration was achieved by
injection of 20 L of 10mM glycine-HCl (pH 2.0). Data were analyzed
using BIAcore software (GE Healthcare).
Transient transduction of pPTK7 or siRNA directed against PTK7
To temporally knock down or overexpress PTK7, cells were transfected
with siRNA directed against PTK7 mRNA (siPTK7), or plasmid (pPTK7),
as previously described.18 In brief, 20 pmol of siRNA was mixed with 1 L
of Lipofectamine 2000 (Invitrogen) to form a transduction complex that
was then added to a culture medium of low serum concentration. After
4 hours of transduction, the medium was changed to normal medium.
Overexpression, and siRNA transduction effectiveness, were confirmed by
real time RT-PCR and Western immunoblotting.
Real-time RT-PCR assay for PTK7
RNA was isolated with RNeasy Micro Kit (QIAGEN) and reverse
transcribed using Superscript III Kit (Invitrogen). Real-time PCR was
performed using TaqMan Universal PCR Mastermix and preformulated
primers for PTK7 (assay ID Mm00613365_ml) and GAPDH (assay ID
Mm99999915_gl; Applied Biosystems). The results were analyzed by the
comparative threshold cycle method and normalized by GAPDH as an
internal control.
Flt-1 and KDR gene silencing
To generate shVEGFR, retrovirus expression vector pSIREN-RetroQ
(Clontech) was used to achieve the expression of short hairpin interference
RNA (shRNA) in MS1 cells. The following inserts were used: KDR,
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shKDR-a (5-ggatgaacattgtgaacga-3) and shKDR-b (5-gctcctgaagatctgtata-
3); Flt-1, shFlt-1-a (5-gagcaaacgtgacttattt-3), and shFlt-1-b(5-gcagcacgct-
gtttattga-3). Each sequence was separated by a 9-nucleotide noncomplemen-
tary spacer from the reverse complement of the same 19-nucleotide
sequence. SMART vector 2.0 nontargeting negative control particle (Thermo
Scientific) was used for nonsilencing control (shNeg).
Retroviral stock solutions were generated by transient cotransfection
with the lentiviral packing vectors psPAX2, pMD2.G and sh-Flt-1, or
sh-KDR into HEK 293T cell by calcium phosphate method. Superna-
tants containing lentiviruses were used to infect MS1 cells overnight.
Cells were selected with 1 g/mL puromycin (Invitrogen) for at least
1 week, and down-regulation of target genes were examined by RT-PCR
and Western blot.
Animals
All animal experiments were approved by the Institutional Animal Care
and Use Committee of the Schepens Eye Research Institute and all mice
were treated according to the Association for Research in Vision and
Ophthalmology Statement for use of animals in Ophthalmic and Vision
Research. Male Balb/c and C57BL/6 mice (6-8 weeks of age) were
purchased from Taconics.
Corneal micropocket angiogenesis assay
This assay was performed as described previously.19 In brief, hydron-
sucralfate pellets (1 g) containing 160 ng/pellet VEGF-A164 were
implanted into pockets surgically created in the avascular corneal
midstroma of anesthetized male Balb/C mice. After pellet insertion,
20 pmol PTK7 siRNA or nonspecific random control siRNA was
subconjunctivally injected, and injections repeated every 2 days. Slit-
lamp photography for neovascularization extent evaluation was per-
formed 7 and 14 days postoperatively. At each observation time, 3 mice
from each group were killed, eyeballs were enucleated, and whole-
mount corneal flaps prepared for CD31 staining of the vascular area.
The details are described in “Immunohistochemical and immunocyto-
chemical staining.”
Wound break assay
Vascular endothelial cell migration was determined by monolayer wound-
healing assays as described previously.20 During these experiments, we
omitted both medium serum and growth factors for 12 hours to mitigate the
effects of migration-enhancing cytokines. All experiments were performed
3 times, at least in triplicate, and a minimum of 3 different areas were
studied in each sample.
Cell proliferation assay
Transfected cells were seeded at a density of 2  105 cells per 100-mm dish
and cultured with VEGF-A. Cell number was counted at each time point
until 72 hours. Serum free DMEM medium was changed once at 48 hours.
Immunohistochemical and immunocytochemical staining
Cells were fixed for 5 minutes in 10% (vol/vol) formaldehyde. Single-label
or double-label immunofluorescence was performed. As controls, samples
were exposed to isotype primary antibodies or irrelevant IgG to measure
nonspecific binding of secondary antibodies. Samples were incubated with
anti-PTK7, -CD31, or -VEGF receptors for more than 2 hours at room
temperature, followed by incubation for 1 hour with TRITC-conjugated or
FITC-conjugated secondary antibodies. After rinsing with PBS, samples
were observed under a fluorescence microscope (a Nikon Eclipse TE200
instrument equipped with a Nikon digital camera, model DXM 1200) using
filters appropriate for fluorescein visualization.
Matrigel assay
HUVECs, MS1, and NIH 3T3 cells were trypsinized, counted, and
resuspended (5  104/mL) in DMEM medium without serum. Some cells
were transfected with siRNA directed against PTK7 before suspension.
Matrigel basement membrane (Chemicon) was suspended in dilution
buffer, without growth factors or heparin, and 150-L aliquots placed into
each well of flat-bottomed 48-well tissue culture plates and allowed to gel
for 1-2 hours at 37°C before cell seeding. Next, cell suspensions were
plated (100 L/ well) onto Matrigel surfaces and incubated at 37°C. Tube
formation and cell migration were observed over the next 36 hours under an
inverted microscope.
Statistics
All data are expressed as mean  SD. Differences between groups
were examined by multivariate analyses using Newman-Keuls test or
ANOVA followed by the Bonferroni procedure for comparison of means
using SPSS 11.0. Values of P  .05 were considered statistically
significant.
Results
PTK7 expression and induction in vascular endothelial cells
We determined PTK7 expression levels in various types of
VECs, and confirmed using immunoblotting that PTK7 was
Figure 1. PTK7 expression and induction in vascular
endothelial cells. (A) PTK7 expression was determined
in HUVECs, a mouse endothelial cell line (MS1), and
bovine arterial endothelial (BAE) cells by Western immu-
noblotting. (B) PTK7 expression was determined in the
presence of 20 ng/mL VEGF-A or FGF-2, or 30 ng/mL
IL-1 or TNF-, added to cells in 6-well plates after
24 hours of serum starvation. Twenty-four hours later,
MS1 cells were collected and immunoblotting performed
(*P  .05, **P  .01, compared with control). (C) Induc-
tion of PTK7 was investigated 24 hours after treatment
with VEGF-A (20 and 50 ng/mL) in MS1 cells using
Western immunoblot.
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highly expressed in such cells, including HUVECs, bovine
arterial endothelial cells (BAEC cells), and MS1 cells (Figure
1A). However, NIH-3T3 dermal fibroblasts did not express
PTK7. To investigate whether vasculogenic and/or proinflamma-
tory cytokines induced PTK7 expression, HUVECs were treated
with 20 ng/mL VEGF-A or FGF-2, or 30 ng/mL IL-1 or
TNF-, for 24 hours and PTK7 expression determined by
immunoblotting. Both VEGF-A and FGF-2 enhanced PTK7
expression in HUVECs, with VEGF-A induction of PTK7
expression occurring (Figure 1B). In contrast, IL-1 and TNF-
suppressed PTK7 synthesis compared with controls. The
VEGF-A induced PTK7 expression was increased in a dose-
dependent manner (Figure 1C).
PTK7 receptor complex formation with Flt-1, Flk-1/KDR, and Flt-4
Although PTK7 was cloned nearly 2 decades ago, ligand or
adaptor molecules that interact with PTK7 remain unknown. To
clarify the mechanisms by which PTK7 mediates VEGF-A–
induced angiogenesis, immunoprecipitation and immunoblot
for 3 types of VEGF receptors and PTK7 were performed.
We found that Flt-1 and PTK7 form a complex in VEC, and
interaction between Flt-1 and PTK7 was enhanced by VEGF-A
(Figure 2A). However, neither Flk-1/KDR nor Flt-4 formed a
complex with PTK7. In addition, the complex formation be-
tween PTK7 and Flt-1 mediated by VEGF-A was found to be
increased in a time-dependent fashion (Figure 2B). After
5 minutes of coincubation with VEGF-A, Flt-1-PTK7 complex
formation commenced and continued to rise over the next
2 hours. KDR-PTK7 complex formation was not found at any
tested levels of VEGF-A (data not shown).
Surface plasmon resonance analysis of receptor complex
formation between Flt-1 and PTK7
To further delineate the nature of the Flt-1/PTK7 interaction, we
used surface plasmon resonance (SPR; BIAcore) analysis. Before
performing the SPR experiment, the purity of each protein was
confirmed by electrophoresis and gel staining (Figure 3A). Flt-1
(R1) and KDR (R2) were found to exist as monomers as well as
dimers in vitro. Moreover, dimer formation was significantly
increased by adding VEGF-A (supplemental Figure 1, available on
the Blood Web site; see the Supplemental Materials link at the top
of the online article).
Either full-length mouse Flt-1 or Flk-1/KDR was immobilized
on a sensor chip surface. Next, full PTK7 or fragment-PTK715-59
was allowed to flow over VEGF receptors immobilized on chip
surfaces. Full-length PTK7 interacted with Flt-1, in a stable and
dose-dependent manner (Figure 3B). On the other hand, fragment-
PTK715-59 showed only a slight SPR increase from baseline, and
was easily removed during washout. However, PTK7 did not
interact with Flk-1/KDR (Figure 3B-C).
To examine whether the Flt-1 interaction with PTK7 was
affected by VEGF-A, we added 50 ng/mL VEGF-A to the PTK7
analyte. This resulted in higher concentration-dependent SPR
(Figure 3D). In the presence of VEGF-A, the maximum interaction
capacity between PTK7 and Flt-1 was increased, and binding
velocity also rose with declined dissociation between PTK7 and
Flt-1. The maximum binding capacity increased up to 4-fold
compared with the binding seen without VEGF-A. In addition,
the intermolecular binding strength was significantly increased
in the presence of VEGF-A, with slower complex breakdown
during the dissociation period. However, another Flt-1 binding
ligand, PIGF, did not affect the interaction between Flt-1 and
PTK7 (Figure 3E).
Phosphorylation of VEGFRs and induction of downstream
signal transduction by PTK7
To investigate the specific VEGFR activation cascades regulated by
PTK7, the phosphorylation of VEGFRs and downstream signals
were investigated using siRNA for PTK7 (siPTK7). The knock-
down effect of PTK7 siRNA for PTK7 expression in VEC was
confirmed (Figure 4A). Then, Flt-1 and Flk-1/KDR activations
were compared between control and siPTK7-transfected VECs as
the first step in studying PTK7-VEGFR signaling. After inhibition
of PTK7, VEGF-induced Flt-1 phosphorylation (but not Flk-1/
Figure 2. Immunoprecipitation and immunoblot for
VEGF receptors and PTK7. (A) Confluent MS1 cells
were collected and lysed 2 hours after treatment with
20 ng/mL VEGF-A (control cells were not so treated).
Immunoprecipitation was performed using 3 g of antibod-
ies specific for Flt-1, Flk-1/KDR, and Flt-4, and with
350-g amounts of protein samples. Precipitates were
collected and immunoblotting performed using antibodies
against either PTK7 or VEGF receptors (**P  .01, com-
pared with control). (B) Receptor complex formation
between PTK7 and Flt-1 was assessed over time by
immunoprecipitation and immunoblotting. MS1 cells,
starved of serum and cytokines for 24 hours, were treated
with 20 ng/mL VEGF-A and collected at various time
points (5, 15, 30, 60, and 120 minutes). Immunoprecipita-
tion and immunoblotting were performed as for panel A.
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KDR phosphorylation) significantly decreased (Figure 4B). Be-
cause phosphorylation of focal adhesion kinase (FAK), and Akt are
important downstream signals after VEGFR phosphorylation, the
activation of the above regulators was determined by siPTK7. The
phosphorylation of FAK was significantly decreased in PTK7-
silenced cells after VEGF-A stimulation (Figure 4C). Similarly,
phosphorylation of Akt by VEGF-A was also inhibited in the
absence of PTK7. Akt phosphorylation began to increase 5 minutes
after VEGF-A treatment of control cells. After silencing of PTK7
expression, however, Akt phosphorylation was significantly de-
layed to 30 minutes, and was suppressed compared with the control
(Figure 4D).
The role of PTK7 in vascular endothelial cell migration and in
vitro angiogenesis
To investigate the specific biologic role of Flt-1 with PTK7
association in angiogenesis, shRNA for Flt-1 and KDR were
designed and transduced into MS1 cell, respectively. After puromy-
cin selection and maintaining several passages, the knock-down
effect of either shFlt-1 or KDR was confirmed by real time RT-PCR
(Figure 5A) and immunoblot (supplemental Figure 2).
In the cell proliferation assay, proliferation was reduced to
38.9% of shNeg in shKDR (P  .0001), and 73.5% of shNeg in
shFlt-1 (P 	 .047; Figure 5B). In the case of siPTK7 cotransduc-
tion, the proliferation activity of shFlt-1 condition was not
changed by siPTK7 transduction (P 	 .112). However, interest-
ingly, cell migration was significantly inhibited in siPTK7-
transduced cells. Cell migration in shFlt-1 with siPTK7 condi-
tion showed 32.5% of shNeg (P  .001) and 44.2% of shFlt-1
only (P 	 .002; Figure 5C). In addition, in wild-type MS1, the
cell migration was significantly inhibited by siPTK7 transduc-
tion (supplemental Figure 3).
As the above results may imply that PTK7 is specifically
associated with cell migration, the expression pattern of PTK7
in wound healing was determined. By immunoblotting, facili-
tated PTK7 expression was observed during wound break assay
Figure 3. Surface plasmon resonance analysis of receptor complex formation between Flt-1 and PTK7. (A) A total of 0.5 or 1.0 g of each purified protein was resolved
in 3%-12% Tris-Bis Native Gel, and stained with Coomassie Blue R250 and then destained (R1, Flt-1, R2, Flk-1/KDR). (B) Purified full-length PTK7 (2M or 4M) or
fragmented PTK715-59 (2.3M or 10M) was allowed to flow over chips bearing immobilized Flt-1 (B) or KDR (C) at concentrations of 500nM. All sensorgrams were corrected
for unbound-chip background. (D) Purified Flt-1 was immobilized at a concentration of 500nM. Full-length PTK7 at different concentrations (0.2, 2 or 4M) was allowed to flow
over the chip surface in the presence or absence of 20 ng/mL VEGF-A. (E) Sensorgram was run with or without PlGF (50 ng/mL) in the same immobilized and analyte
conditions described for panel D. All sensorgrams were corrected for unbound-chip background.
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in a time-dependent manner in VECs (Figure 5D). PTK7
induction began to rise at 6 hours and the enhanced expression
continued to 36 hours after making scratch wound in confluent
monolayer VECs.
To determine the PTK7 distribution pattern in cell migration,
PTK7 immunostaining during wound break assay was per-
formed. Interestingly, PTK7 was found to be more highly
expressed in the cells located at the edge of the wound and the
expression gradually decreased from the wound margin to the
confluent cell area (Figure 5E). From 6 hours after wound break,
PTK7 expression changes were noted and continued (arrow)
until complete wound healing. In addition, lamellipodia or
filopodia of migratory cells expressed a higher PTK7 level than
other parts of the cells (arrowhead).
The effect of PTK7 on in vitro tube formation was also
investigated. Capillary tube length and branch numbers were
significantly down-regulated both in shFlt-1– and shKDR-
transduced cells (Figure 6A-B; supplemental Figure 4). The tube
length was more impaired in shKDR cells than shFlt-1, but the tube
branching impairment was similar between shFlt-1 and shKDR.
Interestingly, additional siPTK7 transduction in shFlt-1 cells caused
more significant suppression in tube branching (48.3%) than in
tube length (15.2%).
Next, we constructed a PTK7-overexpression vector (pPTK7)
to increase PTK7 expression in endothelial cells and to induce
PTK7 synthesis in 3T3 fibroblast cells that normally express low
levels of PTK7. We optimized transduction conditions and ob-
tained enhanced and induced PTK7 expression in MS1 cells and
3T3 fibroblasts, respectively (supplemental Figure 5A). At first, we
introduced pPTK7 in 3T3 fibroblasts, cultured on Matrigel coated
48-well dishes for 24 hours. Interestingly, cell-cell connections for
making tubelike structures were significantly up-regulated under
pPTK7 transduction conditions (supplemental Figure 5B). From
6 hours onward, fibroblasts with pPTK7 transduction formed finely
organized tubelike networks. However, the mock-transduced cells
failed to make mature organized structures until 48 hours after cell
inoculation.
The pattern of capillary network formation in MS1 on Matrigel
showed marked difference among siNeg, siPTK7, and pPTK7
transfection conditions. In siPTK7-treated conditions, the elonga-
tion of cytoplasmic poles was not observed up to 3 days, causing
failure of tubelike network formation. However, in case of the
control vector–transduced condition (mock), tubelike structures
began to form 4 hours after seeding of cells on the Matrigel
surface and the peak response was observed at 16-24 hours. The
finest and most delicate capillary tubes were observed in the
pPTK7 transduction condition. The total length of vascular
network was significantly higher in the mock than the siPTK7
conditions (Figure 6C).
In vivo angiogenesis using micropocket assay
Last, we investigated the role of PTK7 in mediating VEGF-A–
induced angiogenesis in vivo. Mice receiving 160 ng of VEGF-A in
a corneal micropocket were randomly assigned to 2 groups, and
subconjunctivally injected with control siRNA or PTK7-silencing
Figure 4. Phosphorylation of VEGF receptors and its downstream signals by PTK7. (A) Expression of PTK7 24 hours after transduction of siRNA silencing PTK7
(siPTK7), nonspecific random siRNA (siNeg), or lipofectamine only (control; **P  .01). (B) Phosphorylation of Flt-1 and KDR subsequent to PTK7-silencing siRNA
transduction was determined after treatment with 20 ng/mL VEGF-A. When cells were 
 90% confluent, transduction with PTK7-silencing or control siRNA was performed.
Twenty-four hours later, cells were detached, resuspended, and reattached to wells of a 6-well plate. Twenty-four hours after stabilization, cells were treated with 20 ng/mL
VEGF-A and collected for immunoblotting. Immunoblotting was performed using 10% (wt/vol) SDS-PAGE gels, followed by incubation with primary antibodies to each of
phosphorylated Flt-1 (Y1213; 1:1000) and phospho-KDR (Y1054; 1:800). Bands were detected by chemiluminescence (**P  .01). The time courses of FAK (C) and Akt
(D) phosphorylation after PTK7 silencing and VEGF-A treatment were determined by immunoblotting.
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siRNA 0, 1, 3, 5, and 7 days after surgery. To determine the effect of
siPTK7 in vivo, PTK7 mRNA levels were determined in the mouse
cornea by real-time RT-PCR. Compared with the siNeg, siPTK7
subconjunctival injection showed significant down-regulation in
PTK7 mRNA expression (Figure 7A). Suppression of PTK7
expression by siPTK7 was further confirmed by microscopy.
PTK7 expression by the epithelium and anterior stromal kerato-
cyte was significantly reduced by subconjunctival siPTK7
injection (Figure 7B).
Angiogenesis in eyes treated with subconjunctival injections of
PTK7-silencing siRNA was significantly decreased, compared with
controls (Figure 7C). The total vascularized area of the PTK7-
silenced group was suppressed 73% compared with the siNeg-
treated group (P  .0001). In the PTK7-silenced group, initial new
vessel budding from the preexisting blood vessels, as well as
mature new vessels, was less than that seen in the siNeg-treated
group (Figure 7C). Immunohistochemical staining for CD31, in
PTK7-silenced eyes showed significantly decreased vascularized
areas, smaller blood vessel diameter, and less blood vessel branch-
ing than siNeg (Figure 7D).
Discussion
Although PTK7 function has been studied for several years,4,6,16,21,22
the precise mechanisms of action of PTK7 have remained poorly
understood. Here, we show that PTK7 interacts with Flt-1, but not
with Flk-1/KDR or Flt-4, during angiogenesis, using both immuno-
precipitation and physical (SPR; BIAcore) methods. Moreover,
Flt-1 phosphorylation is inhibited in PTK7-silenced endothelial
cells. These findings suggest that PTK7 is essential for activation
and regulation of Flt-1.
The biologic effects of VEGF-A are mediated by 2 high-affinity
receptor tyrosine kinases expressed on endothelial cells, specifically,
Flk-1 (VEGFR2) and Flt-1 (VEGFR1). VEGF-A signaling through
Flk-1 is known to positively regulate endothelial cell proliferation and
migration, whereas the precise function of Flt-1 is still less clear than that
of Flk-1. Flt-1 was originally known as an “inhibitory regulator for
angiogenesis” (for reviews see Ferrara et al10 and Shibuya23). However,
recent studies also suggest that Flt-1 could function as a positive
Figure 5. PTK7 expression and its role in vascular endothelial cell migration. (A) Expressions of Flt-1 and KDR mRNA were determined in short hairpin RNA for
Flt-1(shFlt-1) or KDR (shKDR) transduction conditions by real-time RT-PCR. (B) shRNA-transduced cells were plated at a density of 2  104/well in a 6-well plate and cultured
with VEGF-A (20 ng/mL). Then cell numbers were counted on each time point (**P  .01 vs shNeg). (C) Cell migration after wound breakage was determined by cell restitution
assay. Some shFlt-1–transduced cells were transfected with PTK7-silencing siRNA (E). VEGF-A (20 ng/mL) was added to serum-free medium and cell migration was observed
over the next 36 hours. Migratory cells were counted using inverted phase-contrast microscopy (100; *P  .05, **P  .01). (D) PTK7 expression changes in healing wound
breaks were measured by immunoblotting. After wound breaks were created by pipette tips in confluent cell layers, cell samples were serially collected over the next 36 hours
and immunoblotting was performed as described. Band densities were measured and statistically analyzed (*P  .05, **P  .01). (E) Cells were stained using anti–mouse
PTK7 monoclonal antibody during the wound break assay. MS1 cells were stained 6 hours (left and middle panels) and 18 hours (right panel) after wounding. Enhanced
localized PTK7 expression was observed in the wound margin (white arrow; 200, except bottom right [400]; green: PTK7; blue: DAPI). Arrowhead indicates lamellipodia
and filopodia staining with PTK7 antibody.
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regulator of endothelial cell migration and blood vessel formation.
Kappas and colleagues have reported that Flt-1 modulates Flk-1/KDR
signaling and positively regulates both VEC migration orientation and
blood vessel branching24 and that blood vessel disorganization seen in
the Flt-1 knockdown condition was rescued by transfer of the Flt-1 gene.
In addition, Flt-1 can activate and convey signals for increased DNA
synthesis and cell proliferation, and to activate tyrosine phosphorylation
of PLC and phosphoinositol 3 phosphate kinase (PI3K), which may
amplify the angiogenic response to VEGF.10,11,25,26 Moreover, Nishi and
coworkers have reported that Flt-1 regulates Akt signaling, which plays
a critical role in maintenance of endothelial integrity necessary for blood
vessel stability.27 Taken together, these studies support the concept that
Flt-1 and its downstream signals may be essential not only in maintain-
ing the integrity of healthy blood vessels but also in promoting cell
migration in angiogenesis. Our data suggest that PTK7 may play the role
of an essential coreceptor for inducing angiogenic signaling from Flt-1.
It is notable that VEGF-A enhances the interaction between
Flt-1 and PTK7. In the absence of VEGF-A, the Ka of interaction is
3.7  1.1 (105M1s1). However, the Ka value is increased to
19.3  3.6 when VEGF-A is expressed. In addition, the Kd rises in
the presence of VEGF-A, implying that the VEGF-A binding site of
Flt-1 may not physically overlap with the binding site for PTK7.
Structurally, Flt-1 and PTK7 share similar extracellular regions,
with 7 immunoglobulin-like domains; thus the receptors may form
heterodimers in a manner not unlike the dimerization required for
tyrosine kinase receptor activation. An NMR structural biology
study would help better define this relationship and further assist in
identification of protein segments important in Flt-1 control
functions.
We also demonstrate herein cell migration inhibition after
PTK7-silencing and enhanced in vitro tube formation in Matrigel
when PTK7 is overexpressed. Interestingly, during the wound
break assay, cells migrating to the break area, or at the wound
margin, show higher PTK7 expression than cells farther away from
the margin (Figure 5C). The enhanced PTK7 expression on
migrating cells and their filopodia or lamellipodia may provide a
hint as to the essential role of PTK7 in cell migration. The uneven
PTK7 distribution among the cells in the migratory area may affect
the activation level of Flt-1 in each cell and eventually, to induction
of particular pattern of cell migration and tube formation. Recently,
it has been shown that heterogeneous Flt-1 activation induces
mosaic patterns of VEC proliferation and migration, which may
induce tubelike or blood vessel formation.24 Therefore, PTK7 may
control the migration direction or polarity of VECs by regulating
Flt-1 activation and help to form the normal vascular structure.
The role of PTK7 in cell migration and polarity has been shown
in an embryogenic study. PTK7 knockout in mice is lethal in early
gestation because of defective neural tube closure caused by
Figure 6. Facilitation of in vitro angiogenesis by PTK7 overexpression. (A-B) Endothelial tube formation was compared in shFlt-1, shKDR, and siPTK7 transfection
conditions. Cells were seeded at 4  104/mL into Matrigel-coated wells of a 48-well plate. A camera-equipped inverted microscope was used for photography. Total tube length
(A) and branches (B) were counted at 3 high-magnification images from different areas of each condition; the tube lengths were measured with an image-analysis program
(Image Grabbor Version 1.4, Scion Corp; **P  .01 compared with shNeg). All the experiments were performed 3 times with triplicated samples. (C) In vitro tube formation was
compared using cells transfected with mock, pPTK7, or PTK7-silenced vascular endothelial cells. Twenty-four hours after transductions, cells were collected and seeded at
4  104/mL into Matrigel-coated wells of a 48-well plate. Analysis of tube length was the same method used in panel A. All the experiments were done 3 times with triplicated
samples.
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migration failure.6 Notably, Flt-1 knockout mice have a similar
pattern of loss of cell migration polarity, similar to that seen in the
PTK7 knockout. An earlier study showed that Flt1/ mice have
fully developed endothelial cells but they are not organized into
vascular channels.13 Excessive endothelial proliferation without
mature blood vessel formation may indicate a role for Flt-1 in
endothelial cell migration polarity and maturation of blood ves-
sels.28,29 When these previous mouse knockout studies and our
present work on the need for the interaction between Flt-1 and
PTK7 for successful endothelial cell migration and tube formation
are taken together, we can deduce that Flt-1-PTK7 crosstalk is
essential for endothelial cell migration and tube formation and may
endow a cell with a migration direction. The fact that PTK7
function for cell migration can be effectively inhibited by soluble
PTK7 suggests that the extracellular domain of PTK7 is essential
for its interaction with Flt-1.16,30
In conclusion, our data suggest that PTK7 is critical in
regulation of Flt-1 signal transduction and is essential for
endothelial cell migration. A better understanding of the
mechanisms underlying these phenomena may help to more
precisely define the activities and regulatory nature of Flt-1 in
angiogenesis.
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Figure 7. Inhibition of VEGF-A induced neovascularization by siPTK7. (A) Eight days after corneal pellet insertion, total RNA was extracted from the corneas, and then
expression of PTK7 mRNA was measured by real-time RT-PCR. (B) Confocal microscopic images from postoperative day 7 cornea (green: PTK7; red: Flt-1; blue: DAPI; Ep:
epithelium; P: pellet; St: cornea stroma) magnification200 using a TCS SP2 microscope (Leica). (C) Slit lamp corneal photographs were taken 7 days later and vascularized
areas were measured using image-analysis software (Image Grabbor Version 1.4; Scion Corp). The total vascularized area of PTK7 siRNA injection group was suppressed
73% compared with the control siRNA–treated group (**P  .01). (D) Corneas from both groups were exposed, stained with anti-CD31-FITC antibody, and observed under
fluorescence microscopy (100; Nikon Eclipse TE200 instrument).
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